Takeda teams with enGene for gastrointestinal R&D

Japanese drugmaker Takeda signed a deal with enGene to spotlight new therapies for gastrointestinal disease. Under the agreement, enGene will develop two treatments matching up to Takeda-selected targets through preclinical studies, and the major drugmaker will take the reins from there, promising its partner an upfront payment and milestones tied to R&D. Release

Suggested Articles

A delay to Moderna's phase 3 COVID-19 study is part of a trend of tensions in the biotech’s relationship with the U.S. government, Reuters reported.

GlaxoSmithKline is continuing its strategy of giving out access to its vaccine platform as it adds Medicago to its growing partners list.

Annexon Biosciences and AlloVir are seeking a $100 million IPO apiece in a buoyant market that shows no signs of slowing down.